Renovaro BioSciences Inc. (NASDAQ: RENB), Immunotherapy Biotech Company, Announces Intention to Unite With AI Tech Developer GEDi Cube, Seen as Major Multiplier Effect in the Fight Against Cancer

• Combination of advanced AI machine learning technology and proven immunotherapy technology seen as “future of medicine”
• Demonstrated success that both companies have shown with their innovative developments is expected to expand synergistically
• Potential applications against variety of cancers

The announcement of a binding and exclusive letter of intent to merge, between two of the most innovative companies in their respective fields, is seen as representing a potentially transformative step in the fight against cancer. Considering Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy, that has already demonstrated significant results with its technology against pancreatic cancer, and GEDi Cube, with an AI, machine learning technology that has validated earlier diagnoses of lung cancer in humans, already expanding to 12 additional cancers, combining the companies is being seen as pointing to the future of medicine.

The technology multiplier effect of combining powerful advanced AI processing and machine learning capabilities, and proven leading-edge immunotherapy technology, lifts the fight against cancer to a new level. The success that both companies have shown with their innovative developments is expected to expand synergistically.

Regarding Renovaro, “Dr. Anahid Jewett is a leading cancer immunotherapy researcher at UCLA who has conducted independent, pivotal studies with Renovaro’s technology in different animal models. She has consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response” (https://ibn.fm/sZfWp).

Craig Rhodes, CEO of GEDi Cube International Ltd. “GEDi Cube’s remarkably innovative technology developed over nearly a decade has already validated earlier diagnoses of lung cancer in humans at a leading university hospital and created the technology for 12 additional cancers, including pancreatic and breast cancer.”

Regarding the two companies joining forces, Dr. Mark Dybul, Renovaro CEO, said. “Our advanced cell, gene and immunotherapy techniques are designed to reinvigorate the body’s natural tumor-fighting mechanisms. I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families.”

For more information, visit the company’s website at www.EnochianBio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.